Citations

Clear

421 citation(s) found for "Short, C".

Short-course Versus Long-course Antibiotic Treatment for Ventilator-associated Pneumonia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Singh, Harsimran , Fite, Amsalu, Farooqi, M., Antil, Priya, Tammineedi, Sai Niharika , Gami, NK, Komminni, Praveen Kumar , Taqi, Batoul Ali, Shaikh, Safia , Sahra, Syeda , Faran, Anna, Ahmad, Faran , Singh, H., Farooqi, M., Kakish, Diala Ra’Ed Kamal , Ahmed, Muhammad Saad , Gami, N., Shaikh, S.R.A., Cheema, Huzaifa Ahmad , Ahmad, Sharjeel , Faran, A., Torres, Antoní

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3719-A3719

10.1164/ajrccm.2025.211.abstracts.a3719 Get It

Abstract Rationale: Current guidelines recommend a short course of antibiotic therapy for ventilator-associated pneumonia (VAP) caused by non-fermenting gram-negative bacilli (NF-GNB). However, this approach has been associated with an increased risk of pneumonia recurrence. This meta-analysis aims to address inconsistencies in the literature and evaluate the efficacy of short-course versus long-course antibiotic therapy for VAP, particularly in cases due to NF- GNB. Methods: We systematically searched PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials (RCTs) comparing short versus long courses of antibiotic therapy in patients with VAP. The primary outcomes were the risk of all-cause mortality and pneumonia recurrence. Data were analyzed using RevMan 5.4, with risk ratio (RR) and mean difference (MD) as effect measures. Results: Our pooled analysis included seven RCTs. There was no significant difference in all- cause mortality between short- and long-course antibiotic regimens (RR 1.02; 95% CI: 0.88-1.18; Figure 1). However, a short course of antibiotics increased the incidence ofpneumonia recurrence, particularly in patients with VAP due to NF-GNB (RR 1.64; 95% CI: 1.18-2.29; Figure 1). There were no significant differences between the two regimens regarding the duration of mechanical ventilation (MD 0.01 days; 95% CI: -0.51 to 0.53 days), ICU (MD 0.10 days; 95% CI: -1.00 to 1.20 days) and hospital stay (MD -0.63 days; 95% CI: -3.18 to 1.91 days), or subsequent infection with or acquisition of resistant organisms (RR 0.89; 95% CI: 0.63-1.24). Conclusions: Our meta-analysis suggests that while a short course of antibiotics increases the risk of pneumonia recurrence in NF-GNB VAP, it does not impact mortality compared to a longer course. The clinical significance of the increased recurrence of pneumonia remains uncertain, as it did not result in worse clinical outcomes. A practical approach incorporating validated clinical criteria and biomarker thresholds to guide the duration of antibiotic therapy may be more effective for patients with NF-GNB VAP. Larger RCTs are needed to drawdefinitive conclusions in this population.
The evolving therapeutic revolution in adult acute lymphoblastic leukemia
Kantarjian, Hagop M. , Litzow, Mark R. , Luger, Selina M. , Ribera, Josep‐María , Short, Nicholas J. , Chifotides, Helen T. , Jabbour, Elias , Kantarjian, Hagop , Papayannidis, Cristina , Ribera, Josep-Maria , Short, Nicholas , Chifotides, Helen T , Jabbour, Elias , Jain, Nitin , Papayannidis, Cristina

Mayo Clinic

Cancer | May 5, 2025 | Volume: 131 | Issue: 10 | Pages: No page available

10.1002/cncr.35872 | PMID 40323723 Get It

Abstract The past decade has witnessed remarkable advances in deciphering the pathophysiology of acute lymphoblastic leukemia (ALL) and in developing novel targeted therapies. Basic research and genomic mapping have identified new prognostic biomarkers, targets, and ALL subtypes (e.g., Philadelphia‐like ALL). The ongoing therapeutic revolution in ALL is driven by the addition to the treatment arsenal of therapies that target the ABL fusions, like the BCR::ABL1 tyrosine kinase inhibitors, as well as novel agents that target CD19 and CD22: the CD22 antibody–drug conjugate inotuzumab ozogamicin, the bispecific CD3/CD19 T‐cell engager antibody blinatumomab, and CD19 chimeric antigen receptor T‐cell therapies. These combinations have improved the long‐term survival rates in B‐cell ALL to 70%, and in Philadelphia chromosome‐positive ALL to 80%–90%. The desired goals are to achieve cure rates comparable to those in pediatric ALL and to reduce or eliminate the need for prolonged intensive/maintenance chemotherapy and associated toxicities.
Short‐Term, Mid‐Term, and Long‐Term Outcomes of Transcatheter Aortic Valve Replacement With Balloon‐Expandable Versus Self‐Expanding Valves: A Meta‐Analysis of Randomized Controlled Trials
Tavakoli, Kiarash , Mohammadi, Negin , Bahiraie, Pegah , Saeidi, Sahar , Shaker, Farhad , Moghadam, Arman Soltani , Namin, Sara Montazeri , Rahban, Habib , Pawar, Shubhadarshini , Soleimani, Hamidreza , Jenab, Yaser , Makkar, Raj, Gupta, Aakriti, Mohammadi, Negin Sadat Hosseini , Soleimani, Hamidreza , Hosseini, Kaveh , Tajdini, Masih , Ahmad, Yousif , Iskander, Fady , Alkhouli, Mohamad , Makkar, Raj , Gupta, Aakriti

Mayo Clinic

Clinical Cardiology | April 19, 2025 | Volume: 48 | Issue: 4 | Pages: No page available

10.1002/clc.70134 | PMID 40251970 Get It

ABSTRACTBackgroundComparisons of outcomes after transcatheter aortic valve replacement with balloon‐expandable (BEV) versus self‐expanding (SEV) valves are limited.HypothesisThis study aimed to compare clinical and hemodynamic outcomes of BEV and SEV at short‐term (30 days), midterm (1 year), and long‐term (> 1 year) endpoints.MethodsPubMed, Embase, Scopus, and Cochrane Library databases were searched until July 2024 for randomized controlled trials. Random‐effect model (DerSimonian–Laird method) was used to pool the risk ratios (RR), mean differences, and 95% confidence intervals (CI).ResultsA total of 10 studies comprising 4325 patients (2295 BEV, 2030 SEV) were included. In short‐term, cardiovascular (RR: 0.56, 95% CI: 0.36–0.87) and all‐cause mortality (RR: 0.54, 95% CI: 0.35–0.81) were lower in the BEV group. Risk of moderate to severe paravalvular leak (PVL) was lower among BEV patients in short‐term (RR: 0.28, 95% CI: 0.17–0.49) and long‐term (RR: 0.28, 95% CI: 0.1–0.79). A limited number of studies showed a greater risk of clinical valve thrombosis on BEV in midterm and long‐term. The need for permanent pacemaker implantation was lower in BEV at both short‐term (RR: 0.56, 95% CI: 0.37–0.87), and midterm (RR: 0.78, 95% CI: 0.64–0.94). The SEV group had a larger effective orifice area with lower mean transvalvular pressure gradient at all endpoints.ConclusionsBEV is associated with reduced risk of clinical outcomes in short‐term; however, most differences diminish in longer evaluations, except for moderate to severe PVL, which remains elevated for SEV. SEVs had better hemodynamic results and lower risk of clinical valve thrombosis.
Women Physicians in Leadership Roles in Critical Care Medicine or Academic Medicine—A Systematic Literature Review
Siddiqui, Shahla , Gali, Bhargavi , Cotter, Elizabeth , Short, Margo, McNichol, Megan , Mulaikal, Teresa A., Cassavaugh, Jessica , Chow, Jarva, Russell, Cortessa, Golhar, Shweta Yemul, Ben-Jacob, Talia K., Siddiqui, Shahla

Mayo Clinic

Critical Care Explorations | March 30, 2025 | Volume: 7 | Issue: 4 | Pages: e1249

10.1097/cce.0000000000001249 | PMID 40153554 Get It

OBJECTIVE: To systematically review and synthesize the evidence surrounding factors impacting women rising to leadership positions in critical care medicine (CCM). DATA SOURCES: PubMed, Embase, Web of Science, and Cochrane Library from 2011 to 2024. STUDY SELECTION: Articles included were cohort studies, surveys, and interviews addressing women physicians practicing in CCM and related fields of academic medicine. DATA EXTRACTION: Causes of not rising to leadership among women were extracted and tabulated along with other pertinent study characteristics. DATA SYNTHESIS: The database searches generated 892 records. Thirty-nine studies met inclusion criteria for data extraction. The included articles represented seven countries, with 30 studies originating in the United States. Only two studies were from CCM, whereas others addressed leadership in other academic and clinical fields of medicine, medical journals, and societies and medical faculty. Twenty-six studies were qualitative, observational studies; five were survey based and eight included interviews. Using thematic analysis, the following five domains emerged: pipeline issues, lack of opportunities, lack of self-efficacy, lack of mentorship, and sustaining women in leadership. CONCLUSIONS: While the satisfaction rates of women in CCM were high, challenges remain for women to obtain leadership opportunities. A culture of support could better nurture and sustain women in leadership roles. More CCM-focused gender bias research is needed. Future targets for interventions include gender bias training, awareness, and developing strategies to break through the cycle of gender preferential promotions in CCM.
Transmeatal Urethral Surgery: Short Strictures Techniques and Early Outcomes
Tolbert, Sierra, Premo, Hayley , Olive, Elizabeth J. , Ungerer, Garrett , Anderson, Katherine T. , Warner, Jonathan N. , Lee, Yeonsoo Sara , Findlay, Bridget L. , Viers, Boyd R.

Mayo Clinic

Videourology™ | March 27, 2025 | Volume: 39 | Issue: 1 | Pages: 1-2

10.1089/vid.2024.0082 Get It

Introduction and Objectives: Urethral stricture disease is a challenging urologic problem with a high recurrence rate. Initial management is typically completed endoscopically (e.g., urethral dilation, direct visual internal urethrotomy); however, guidelines recommend against repeated endoscopic management. Currently, surgical urethroplasty or intermittent catheterization remains the only other option. We have demonstrated a minimally invasive approach to urethroplasty. In this video, we aim to demonstrate the techniques and early outcomes of transmeatal urethral surgery for short urethral strictures. Materials and Methods: We demonstrate the procedure in two different individuals with idiopathic bulbar urethral strictures less than 2 cm. The patient is prepped in dorsal lithotomy position. Under direct visualization via cystoscopy, the ventral place of the urethral stricture is first incised to a goal of 26 Fr lumen. Next, mucosal realignment is completed via LSI Solutions’ URTRAC sheath and the RD 180 endoscopic suturing device. Two sutures are placed on either side of the urethrotomy incision site, allowing the proximal and distal ends of the mucosa to be pulled perpendicular to the urethrotomy. After reapproximation, a titanium knot is introduced endoscopically to anchor each suture into place. An indwelling catheter is then left in place. Patients are then seen at four months postoperatively. Results: Out of four total patients, there is a 100% success rate cystoscopically at 4 months postoperatively. There have been no recorded intraoperative or postoperative complications. The average operating room time was 54 minutes, and the average estimated blood loss was 9 mL. Conclusions: Transmeatal urethral surgery for short strictures via incision and urethral reapproximation appears to be a safe and effective repair option for the management of short urethral strictures. All research procedures were carried out in accordance with ethical guidelines and institutional policies, reviewed by the IRB. Authors have received and archived patient consent for video recording/publication in advance of video recording of procedure. The authors declare that there are no commercial associations or financial interests in any product or service discussed in this article that might create a conflict of interest. The authors have not engaged in any activities or relationships with commercial entities that would bias or influence the content of this study. Runtime of video: 5 mins 40 secs.
High-Power Short-Duration Ablation versus Conventional Power Ablation in Pulmonary Vein Isolation in Patients with Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
Cabral, David C. B. I. , Rivera, André , Braga, Marcelo Antonio Pinheiro , Passos, Bárbara Mariz Ferreira, Brígido, Alexandra Régia Dantas , Carvalho, Guilherme Dagostin de , Deshmukh, Abhishek , DeSimone, Christopher V. , DeSimone, Christopher V , Félix, Iuri Ferreira , Ternes, Caique M. P. , Rivera, A

Mayo Clinic

No container title available | February 22, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.174024725.57612852/v1 Get It

Introduction: High-power short-duration (HPSD) ablation has emerged as a promising alternative to conventional power delivery (CPD) for pulmonary vein isolation (PVI) among patients with atrial fibrillation (AF). However, its efficacy, procedural efficiency, and safety profile remain uncertain. Methods: PubMed, Embase, Cochrane Library and ClinicalTrials.Gov databases were systematically searched for randomized controlled trials (RCTs) comparing HPSD with CPD ablation for PVI in patients with AF. Random-effects models were used to pool hazard ratios (HR) and risk ratios (RR) with 95% confidence intervals (CI). R version 4.4.2 was used for statistical analysis. Results: Seven RCTs with 1,006 patients (514 HPSD, 489 CPD) were included. No significant differences were found in freedom from arrhythmia during the follow-up period (HR 0.77; 95% CI 0.41–1.45; p=0.424). AF recurrence did not differ (RR 0.94; 95% CI 0.65–1.36; p=0.733) between groups. HPSD had a significantly shorter procedural (MD -22.61 min; 95% CI -33.18, -12.04; p<0.001) and RF ablation times (MD -15.70 min; 95% CI -20.86, -10.55; p<0.001). No differences were observed in fluoroscopy time and first-pass isolation for right and left pulmonary veins. There was no difference in esophageal lesion rates, pericardial, or neurological complications, but there was a higher incidence of steam pops in HPSD (RR 3.42; 95% CI 1.45–8.09; p=0.005). Conclusion: In patients with AF undergoing PVI, HPSD did not increase freedom from arrhythmia as compared with CPD ablation, however it was associated with shorter procedure and RF ablation times with a similar safety profile.
A Prospective Observational Study of the Short-term Benefits of Pulmonary Rehabilitation in Connective Tissue Disease-related Interstitial Lung Diseases
Gedert, Rosemary J. , Huang, Suiyuan, Sabbagh, Maya, McInroy, M., Khanna, Dinesh, Nagaraja, Vivek , Khanna, Dinesh , Khanna, Dinesh , Huang, Steven Y.

Mayo Clinic

Indian Journal of Rheumatology | February 8, 2025 | Volume: 20 | Issue: 2 | Pages: 135-140

10.1177/09733698241310941 Get It

Background and Objectives: Interstitial lung disease (ILD) is a common manifestation of connective tissue disease (CTD). (a) Pulmonary rehabilitation (PR) can be utilised to improve dyspnoea and quality of life in patients with chronic lung conditions, including both obstructive and restrictive lung diseases. (b) This study aims to determine if PR can be a useful therapy to improve functional capacity and self-reported measures of dyspnoea in patients with CTD-ILD. Methods: Patients with a diagnosis of CTD-ILD at a tertiary centre were prospectively enrolled to receive PR in this study. The primary outcome was a change in the 6-minute walk test (6MWT) between baseline and 8 weeks after PR. The secondary outcome measures included pulmonary function tests (PFTs) and Patient-Reported Outcomes Measurement Information System (PROMIS→) Dyspnoea, St George’s Respiratory Questionnaire (SGRQ), and Leicester Cough Questionnaire (LCQ), which were collected before and at 8 weeks after PR. P < .05 was considered statistically significant. Results: Twenty-one patients were included in the data analysis. The baseline characteristics are shown in Table 1 . Following PR, there was a statistically significant improvement in the 6MWT ( Figure 1 ). Improvement in scores was observed in LCQ and the symptom domain of the SGRQ. Trends towards improvement were noted in PROMIS → Dyspnoea scores. Conclusion: In CTD-ILD patients, an 8-week course of PR led to improvements in functional capacity (6MWT) and certain quality of life domains (LCQ and symptom domain of SGRQ). Future studies are required to determine the longer-term benefit of PR in CTD-ILD patients and if these improvements are sustained.
156: WEIGHTY MATTERS: OBESITY AND SURVIVAL IN HEART TRANSPLANT RECIPIENTS BRIDGED WITH SHORT-TERM MCS
Chaudhary, Ashlesha , Singletary, Audrey, SAHAJWANI, JUHI , Rodriguez, Allison Perez, Patel, Parag, Chaudhary, Sanjay

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001099288.45656.b6 Get It

P-1650. Clinical Outcomes among Patients Prescribed Suboptimal Antibiotic Therapy on Discharge to Nursing Homes
Short, Emily K. , Chan, Dominic , Hildebrand, Andrea , Nguyen, Thuan , Zhou, Michelle H, Santos, Emily , Ham, YoungYoon , Shephard, Emily, McCracken, Caitlin M. , Noble, Brie N. , Crnich, Christopher J. , Zhou, Michelle H, McGregor, Jessina C. , Jolles, Sally A. , Bearden, David T. , Izumi, Shigeko , Furuno, Jon P.

Mayo Clinic

Open Forum Infectious Diseases | January 29, 2025 | Volume: 12 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofae631.1816 Get It

Abstract Background Little is known regarding outcomes for patients prescribed antibiotics on discharge from the hospital to nursing homes (NHs). We quantified the association between suboptimal antibiotic prescribing and clinical outcomes at discharge to NHs. Methods This was a multicenter, retrospective cohort study of adult (age &gt;18 years) patients prescribed systemic antibiotics on discharge from 9 acute care hospitals in Oregon, Washington, and Wisconsin to a NH from 2016 – 2018. Study data were electronically extracted from hospital and NH electronic health records and supplemented with chart review. Suboptimal antibiotic therapy was determined by an infectious disease pharmacist or physician using clinical information (e.g., antibiotic regimen, indication, and culture results) available at discharge. Outcomes included emergency department (ED) visits, hospital readmissions, or Clostridioides difficile infection (CDI) within 30 days of hospital discharge. Comparison of outcomes between patients with suboptimal and non-suboptimal antibiotic therapy were tested by chi-squared tests. Results Among 280 included patients, mean (SD) age was 76.0 (11.5) years, 35.7% (n=100) were male, and median (IQR) inpatient length of stay was 6 (4-9) days. The most prevalent antibiotic indications were urinary tract infections (n =109, 38.9%), lung indications (n=60, 21.4%), and prophylaxis (n=29, 10.4%). Among 317 antibiotic prescriptions, the most frequently prescribed antibiotic classes were cephalosporins (n=83, 29.6%), fluoroquinolones (n=57, 20.4%), and beta-lactam/beta-lactamase-inhibitors (n=40, 14.3%). Fifty-eight patients (20.7%) were prescribed suboptimal antibiotic therapy on hospital discharge. There were no significant differences in the frequency of 30-day ED visits (14% vs 11%, p=0.76) or hospital readmission (19% vs 18%, p=0.94) between patients prescribed and not prescribed suboptimal antibiotics; however, suboptimal antibiotics were significantly associated with CDI within 30 days of discharge (10% vs 2%, p=0.01). Conclusion Suboptimal antibiotic prescribing on discharge to NHs was associated with increased risk of CDI within 30 days of discharge. This finding may inform interventions to improve antibiotic prescribing on discharge to NHs. Disclosures YoungYoon Ham, PharmD, Gilead: Honoraria Jon P. Furuno, PhD, Merck & Co., Inc: Grant/Research Support
Short-term and long-term prognoses in AChR-Ab positive very-late-onset myasthenia gravis patients
Xie, Nairong , Liu, Qing , Wang, Yaye , Di, Li , Zhu, Wenjia , Wen, Xinmei , Shen, Xin‐Ming , Da, Yuwei , Da, Yuwei , Wen, Qi, Liu, Haoran , Jiang, Yuting , Lü, Yan , Di, Li, Wang, Min , Zhang, Xuxiang

Mayo Clinic

Therapeutic Advances in Neurological Disorders | January 8, 2025 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17562864241309793 | PMID 39803329 Get It

Background: Very-late-onset myasthenia gravis (VLOMG) refers to myasthenia gravis (MG) with onset at age 65 or older. Current research on VLOMG prognosis remains limited, especially regarding factors influencing outcomes. Objectives: To identify the clinical factors that affect the short- and long-term prognosis of MG patients with an onset age ⩾65 years. Design: This was a single-center, retrospective cohort study of AChR-ab positive VLOMG patients, classified into two subgroups based on age of onset: sub-very-late-onset MG (S-VLOMG, onset age ⩾65 and <75 years), and super-late-onset MG (SLOMG, onset age ⩾75 years). Methods: A total of 93 patients were included, including 75 in the S-VLOMG group and 18 in the SLOMG group. Clinical, therapeutic, and prognosis data were reviewed, and the Cox regression model was used to identify factors influencing short- and long-term prognosis. Results: Patient characteristics were well balanced between the groups. Overall, 49.5% of patients achieved minimal symptom expression (MSE) within 6 months and 86% within 24 months. There was no significant difference between the groups in the proportion achieving MSE at 6 months ( p = 0.635) or 24 months ( p = 0.714). The median time to achieve MSE was also comparable between the S-VLOMG and SLOMG groups (199.0 days vs 280.5 days, p = 0.463). Low baseline MG-ADL score and steroid therapy were associated with better short-term prognosis ( p = 0.007 and p = 0.002, respectively). For long-term prognosis, baseline bulbar and limb involvement, time to treatment initiation, and use of immunosuppressants were significant factors ( p = 0.025, p = 0.004, p = 0.025, and p < 0.0001, respectively). There were no significant differences in side effects or drug withdrawal rates between two groups. Conclusion: This study demonstrated that AChR-ab positive VLOMG patients have a favorable prognosis and responded well to medication, with age and comorbidities showing no significant impact.